EU Cuts Toddler COVID Vaccine Series to Two Doses

Children aged 6 months through 4 years in Europe now need two primary doses instead of three.

Updated on Nov. 2, 2026 in Children’s Health

Close view of a plain unlabeled glass vial of pale liquid beside a small empty syringe on a light grey surface under soft daylight.
The European Commission approved cutting the Pfizer-BioNTech COVID-19 vaccine primary series for children aged 6 months to 4 years from three doses to two. AI Illustration. Upload story photo >

Live Poll

Do you trust doctors' recommendations on childhood vaccines for your children?

The European Commission approved an update to the Pfizer-BioNTech COVID-19 vaccine for children aged 6 months through 4 years, reducing the primary series from three doses to two. The authorization covers the European Union, Iceland, Liechtenstein and Norway, and was announced May 29, 2026.

Why it matters

A shorter primary series means fewer clinic visits for families with infants and toddlers, which can make keeping a young child's vaccination schedule on track easier. Doses for children aged 5 through 11 remain unchanged, so the update affects only the youngest age group.

This is a regulatory authorization update, supported by the European Commission's review of available data including safety data. The source does not provide the specific study design, sample size, or measured effect sizes behind the two-dose schedule.

The players

Pfizer

Pfizer is a global pharmaceutical company with a long-standing portfolio across vaccines, oncology and other therapeutic areas, and co-develops the Pfizer-BioNTech COVID-19 vaccine.

BioNTech

BioNTech is a German biotechnology company known for mRNA-based therapies, and it is the Marketing Authorization Holder for the Pfizer-BioNTech COVID-19 vaccine in the United States, the EU, the United Kingdom and other countries.

European Commission

The European Commission is the executive body of the European Union that grants EU-wide marketing authorizations for medicines and vaccines after scientific review.

The details

The updated authorization changes only the primary vaccination series for children aged 6 months through 4 years, cutting it from three doses of 3-μg each to two. For children aged 6 months through 11 years, the Pfizer-BioNTech vaccine is given as a 10-μg dose, and the recommendation for ages 5 through 11 remains a single 10-μg dose. The authorization is valid across all 27 EU Member States, Iceland, Liechtenstein and Norway.

Timeline

  1. May 29, 2026: Pfizer and BioNTech announced the European Commission's approval of the pediatric vaccine update.

Health Landscape

The change sits within the European Commission's centralized authorization system for vaccines, which governs how the Pfizer-BioNTech COVID-19 vaccine is approved across EU member states and partner countries. It adjusts the pediatric dosing framework for the youngest age group while leaving the 5-to-11 recommendation untouched.

If you have a child between 6 months and 4 years old in the EU, Iceland, Liechtenstein or Norway, the primary series now requires two doses instead of three, so it is worth asking your pediatrician whether the schedule applies to your child. Families elsewhere should check local guidance, since this authorization applies only in the countries named.

The takeaway

The core insight is that the youngest children now need one fewer dose in their primary series, while the schedule for older children is unchanged. Talk with your child's pediatrician about how the updated schedule fits your child's vaccination plan.

Further reading

For more on how vaccine schedules are set for young children, explore our Children's Health coverage.

Source note: This article includes information reported by Firstwordpharma.

Live Poll

Do you trust doctors' recommendations on childhood vaccines for your children?